Innovent Biologics got approval from the National Medical Products Administration (NMPA) to start clinical trials for its IND application for IBI318, a recombinant fully human bispecific antibody targeting programmed cell death protein 1 (PD-1) and an undisclosed target for a tumor-associated antigen (TAA), in patients with hematological and advanced solid tumors.
Michael Yu, Founder, Chief Executive Officer and Chairman of Innovent, said that IBI318 is one of the exciting, innovative anti-cancer programs that Innovent has pursued.
He said the company has a few bispecific antibody product candidates that have reached the clinical stage of development in both oncology and ophthalmology therapeutic areas.
According to Yu, many of those projects have the potential to be global first-in-class assets that could help large numbers of patients in need.
“The IND approval by NMPA of the bispecific antibody IBI318 has confirmed Innovent’s ability to innovate and encouraged us to continue our pursuit of global innovation,” he said.
by Dino Mustafić